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Abstract
Background: The function of the thymic microenvironment is to promote thymocyte maturation,
in part via regulation of thymocyte proliferation and cell death. Defects in fetal thymic epithelial cell
(TEC) development and function, and therefore in the formation of a functional microenvironment,
can be caused either directly by TEC differentiation defects or indirectly by defective thymocyte
maturation. In this paper we studied fetal thymocyte proliferation during the early transition from
the CD3-4-8- (triple negative, TN) to CD4+8+ (double positive, DP) stages. We compared wild
type mice with Rag1-/- mice and with Hoxa3+/-Pax1-/- compound mutant mice, which have blocks at
different stages of thymocyte development.
Results: Wild type fetal and adult thymus showed stage-specific differences in the proliferation
profiles of developing thymocytes, with fetal stages showing generally higher levels of proliferation.
The proliferation profile of fetal thymocytes from Rag1-/- mutants also had stage-specific increases
in proliferation compared to wild type fetal thymocytes, in contrast to the lower proliferation
previously reported for thymocytes from adult Rag1-/- mutants. We have previously shown that
Hoxa3+/-Pax1-/- mice have abnormal fetal TEC development, resulting in increased apoptosis at the
TN to DP transition and decreased DP cell numbers. Fetal thymocytes from Hoxa3+/-Pax1-/-
compound mutants had increased proliferation, but fewer proliferating cells, at the DP stage. We
also observed a decrease in the level of the cytokines IL-7 and SCF produced by Hoxa3+/-Pax1-/-
TECs.
Conclusion:  Our results indicate complex and stage-specific effects of abnormal TEC
development on thymocyte proliferation.
Background
Thymocyte development occurs within a complex net-
work of cells, extracellular matrix, and secreted factors re-
ferred to as the thymic microenvironment [1]. Current
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evidence suggests that this microenvironment is created
during fetal thymus organogenesis through stage-depend-
ent interactions between differentiating thymic epithelial
cells (TECs) and developing thymocytes [2–6]. Therefore,
blocks at different stages of thymocyte development result
in differential effects on TEC differentiation and function.
Because of the complex interdependence of TEC and thy-
mocyte differentiation, defects in fetal TEC development
can be caused either directly by cell-autonomous TEC dif-
ferentiation defects, or indirectly by defective thymocyte
maturation. Once a mature thymic environment is
formed, many, if not all stages of thymocyte maturation
require interactions with thymic epithelial cells. There-
fore, defects in TECs can in turn cause defects in thymo-
cyte differentiation, proliferation, or cell death.
Thymocyte differentiation undergoes two main transi-
tions. The first is from the CD3-4-8- (triple negative, TN)
to the CD4+8+ (double positive, DP) stages. During this
transition, T cell precursors sequentially gain and lose cell
surface expression of CD44 and CD25 markers, express
the pre-T cell receptor (pTCR), and undergo β-selection
[2,7–9]. The other transition is from CD4+8+ DP to CD4+
or CD8+ single positive (SP) thymocytes, in which DP
cells express CD3, rearrange their α-TCR, undergo positive
and negative selection, and down regulate CD4 or CD8 to
become functional CD8+ or CD4+ SP T cells [10,11]. In
addition to functional and cell surface marker changes,
each thymocyte differentiation stage is marked by charac-
teristic changes in proliferation and apoptosis [12–18].
The most well defined role for TECs in directly affecting
thymocyte differentiation is to mediate positive selection
via expression of MHC molecules [11,19–22]. However, it
is still unclear whether TECs directly promote specific
stages of thymocyte differentiation during stages that do
not involve MHC-TCR interactions, or whether their role
at other stages is primarily to promote cell growth and /or
survival. Cytokines produced by TECs have been shown to
promote proliferation in early stages of thymocyte devel-
opment, and have been proposed to regulate apoptosis
and differentiation, although their precise roles remain
controversial [23,24]. TECs have also been shown to pro-
mote thymocyte proliferation in SP cells after selection
has occurred [15]. However, a defined role for TECs at the
TN-DP transition remains elusive. Much of the research
on this transition has focused on the role of the pre-TCR.
Mounting evidence suggests that the pre-TCR does not re-
quire interaction with a ligand to perform its function,
and the subsequent CD44-25- (TN4 or pre-DP) to DP
transition has been termed "programmed differentiation"
to indicate that this step can occur in isolated thymocytes,
presumably without input from extrinsic signals [25–27].
However, there is also evidence that the thymic microen-
vironment does contribute signals required for the TN-DP
transition, particularly to promote thymocyte prolifera-
tion and apoptosis [13,28–30]. The specific nature and
purpose of the TEC contribution during this important
transition therefore remains to be determined.
In order to investigate the regulation of thymocyte devel-
opment by TECs, we are studying Hoxa3+/-Pax1-/- com-
pound mutant mice. Hoxa3 and Pax1 are transcription
factors that act in a common pathway regulating thymus
organogenesis and thymic epithelial cell development
[29,31–34]. Hoxa3+/-Pax1-/- compound mutants have de-
fects in TEC development including reduced numbers of
TECs, fewer MHC Class II+ TECs, and changes in TEC pro-
liferation and apoptosis. These TEC defects result in thy-
mocyte maturation defects that include a decrease in total
thymocyte number and a 10-fold reduction in the number
of DP thymocytes, but an apparently normal transition
from the TN3 to the pre-DP stage. The decrease in DP cells
is associated with increased apoptosis in both pre-DP and
DP cells [29]. As the defects at the TN to DP transition in
these mutants are caused by defective TEC function rather
than thymocyte-intrinsic defects, these mice represent an
opportunity to study the role of TECs in promoting this
transition.
To further investigate the role of TECs in promoting thy-
mocyte death and growth during the TN to DP transition,
we assayed the proliferation of specific thymocyte subsets
using BrdU incorporation, which detects cycling cells in S-
phase. We compared fetal and adult wild type mice with
Hoxa3,Pax1 compound mutants [29,34]. We also assayed
Rag1-/- mice, which have defects in TEC development due
to arrested thymocyte maturation at the TN3 stage [35].
We found stage-specific differences in proliferation levels
between fetal and adult wild type thymocytes. We also
found distinct patterns of thymocyte proliferation in the
Rag1-/- and Hoxa3,Pax1 mutants. The abnormal cell death
and proliferation patterns in the Hoxa3,Pax1 compound
mutant fetal thymocytes might be caused in part by ob-
served reductions in the transcription levels of the cy-
tokines IL-7 and SCF produced by TECs. Our results
support a critical role for microenvironment created by
TECs in regulating thymocyte proliferation during the TN
to DP transition, and show that this function is disrupted
in Hoxa3,Pax1 compound mutants.
Results
Thymocyte proliferation patterns are different in fetal and 
adult wild type mice
As an initial analysis, we compared thymocyte prolifera-
tion between thymocytes from late fetal (E17.5) and adult
(6–8 week) wild type C57BL6/J mice. Although differenc-
es in the proliferation of fetal vs. adult TCR-expressing
thymocytes and have been reported [36], we were interest-
ed in investigating the more immature thymocyte subsets.BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/12
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Figure 1
DNA synthesis patterns of fetal vs. adult thymocyte subsets as measured by incorporation of BrdU A. Thymo-
cytes were gated as either CD3-4-8- TN or CD3+4+8+ DP by cell surface marker expression and forward scatter (SP cells
should be located between these two gates, and therefore excluded from analysis). B. Gate used for analysis of BrdU incorpo-
ration on gated subpopulations. Panels C-E show CD44 vs. CD25 dot plots of the gated CD3-4-8- population from 5–6 week
old adult C57BL/6 (C), E17.5 fetal C57BL/6 (D), and E17.5 fetal RAG-/- (E). Percentages are shown in each quadrant. F. Percent-
ages of BrdU+ cells (Mean ± SEM) in each subset of TN cells defined by CD44 and CD25, and in DP cells. G. Adult wild-type
thymocytes were gated as CD3-4-8-B220-NK1.1-. H. CD44 vs. CD25 dot plots of the gated population from (G). I. Percentage
of BrdU+ cells (mean ± SEM) in adult and fetal TN1 thymocytes excluding B and NK cells (H, G).BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/12
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BrdU labeled fetal and adult thymi were analyzed for the
percent of proliferating cells in different CD3-4-8- TN thy-
mocyte subsets defined by CD44 and CD25 expression
[8]. The CD3+4+8+ population was defined by co-staining
of all three markers (Fig. 1A). A typical analysis of the Br-
dU+ cells in DP cells and the four CD44 vs. CD25 subsets
within the TN cell population is shown in Figure 1. Com-
piled data for each subset from all experiments is shown
in Table 1.
The wild type adult (Fig. 1C, 1F) and fetal (Fig. 1D, 1F)
thymocyte proliferation profile patterns differed signifi-
cantly at specific stages. The overall proliferation level in
TN cells was increased by 50% in fetal thymocytes (p <
0.01). Most dramatically, the percentages of BrdU+ cells in
fetal thymocytes were 10-fold higher than in the adult at
the earliest, TN1 (CD44+25-) thymocyte differentiation
stage (P < 0.001). A much lower, but still significant in-
crease was seen in fetal TN2 cells (25% increase, p < 0.01).
Proliferation was also significantly higher at the fetal TN3
stage compared to adult (50% increase, p < 0.01). Prolif-
eration at the TN4/pre-DP (CD44-25-) stage was similar
between fetal and adult thymocytes. In contrast, DP cells
showed a 3-fold increase in proliferation in the fetal thy-
mus relative to adult (p < 0.01). Therefore, nearly every
stage from the earliest TN to the DP stages showed signif-
icantly increased proliferation in fetal thymocytes relative
to adults.
It was possible that the lower percentage of proliferating
cells seen in the TN1 population in adults was due to an
increased number of B cells and NK cells in the adult thy-
mus, which would not have been excluded in our initial
analysis. As this was one of the most striking differences
seen between fetal and adult stages, we repeated this anal-
ysis adding antibodies against B220 and NK1.1 to CD3, 4
and 8 in the excluded gate (Fig. 1G, 1H). Even excluding
these cell populations, there is still a significantly lower
percentage of proliferating cells in the TN1 population in
the adult thymus than in the fetal thymus (Fig. 1I). There-
fore, this difference is not due to different numbers of B
and NK cells in the adult vs. fetal thymus.
Rag1-/- fetal thymocytes have a stage-specific increase in 
proliferation relative to wild type
We also compared proliferation of fetal thymocytes from
Rag1-/- mice to the results obtained from wild type mice.
Thymocytes in the adult Rag1-/- thymus have been previ-
ously shown to have overall lower levels of proliferation
than adult wild type TN thymocytes [13], particularly at
the TN3 stage [37–40]. At fetal stages, our results showed
that proliferation also varied between thymocytes in the
wild type and Rag1-/- thymus at discrete stages of thymo-
cyte differentiation. At the earliest TN1 stage, thymocyte
proliferation levels in Rag1-/- thymi were similar to fetal
wild type cells (Fig. 1E, 1F; Table 1). At the TN2 stage, fetal
thymocytes from Rag1-/- mice had a proliferation level
nearly twice that of wild type fetal thymocytes (p < 0.001).
By the TN3 stage, the percentage of proliferating Rag1-/-
thymocytes had dropped slightly below that of wild type
fetal thymocytes (~30% decrease, p < 0.01), equal to wild
type adult TN3 proliferation levels. In addition, the per-
centages of BrdU+ cells in TN1 and TN2 subsets in the
Rag1-/- fetal thymus were significantly higher than those
of the wild type adults (P < 0.001). These results with
Rag1-/- fetal thymocytes contrast with thymocytes in the
Rag-/- adult, which have much lower proliferation than
wild type adult thymocytes at all stages of thymocyte dif-
ferentiation [13].
Thymocyte proliferation in Hoxa3+/-Pax1-/- thymocytes at 
the TN-DP transition
Our previous analysis of the Hoxa3+/-Pax1-/- compound
mutant thymocyte phenotype showed a specific partial
block at the TN to DP transition, associated with increased
apoptosis at both the TN4/pre-DP and DP subsets, and a
Table 1: Percentage (Mean ± SD) of BrdU+ cells in each subset of fetal thymocytes
Group Total Cell
#(X105)
No. CD44+ CD25- CD44+ CD25+ CD44- CD25+ CD44- CD25- CD4+ CD8+ CD3+ In All
DN
wt Adult NC 8 2.04 ± 0.53* 15.83 ± 1.73* 15.38 ± 3.36* 34.73 ± 11.43 6.07 ± 1.19* 18.4 ± 5.14*
wt Fetal 42.72 ± 3.88 23 18.05 ± 8.67 20.99 ± 10.66 22.82 ± 8.33 41.78 ± 14.87 19.05 ± 8.12 27.6 ± 8.79
Pax1+/- 32.14 ± 2.15 22 14.86 ± 8.97 19.12 ± 6.985 16.70 ± 5.47 35.32 ± 14.82 20.80 ± 10.0 24.3 ± 7.38
Hoxa3+/- 29.25 ± 3.43 13 18.06 ± 9.20 22.87 ± 11.45 19.14 ± 8.73 29.89 ± 15.17 17.02 ± 10.04 21.2 ± 7.23
Pax1-/- 22.38 ± 4.98 4 18.97 ± 11.50 21.67 ± 4.10 26.31 ± 7.35 45.59 ± 16.90 28.61 ± 9.46 24.8 ± 9.05
Hoxa3+/-Pax1-/- 7.96 ± 1.12 6 19.58 ± 8.52 25.28 ± 5.55 22.79 ± 4.56 44.87 ± 14.15 35.37 ± 6.414 25.8 ± 6.54
RAGnull UC 14 16.57 ± 3.12 37.70 ± 7.89** 14.33 ± 3.16** - - 11.2 ± 3.3**
* P < 0.01, significant differences between wild type fetal and adult. 
** P < 0.01, significant differences with fetal wild type. 
*** NC: not count. BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/12
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Figure 2
Proliferation of E17.5 Hoxa3-Pax1 compound mutant thymocytes compared to wild type. Panels A-B show CD44
vs. CD25 dot plots of the gated CD3-4-8- population from E17.5 wild type (A) and Hoxa3+/-Pax1-/- (B) thymus. Percentages are
shown in each quadrant. C. Percentages of BrdU+ cells (Mean ± SEM) in each of 4 subsets of TN cells defined by CD44 and
CD25, and in DP cells. D, E. CD44 vs. CD25 dot plots of the gated CD3-4-8- population divided into five subsets as defined by
[12]. F. Percentages of BrdU+ cells (Mean ± SEM) in each of 3 CD44- TN subsets defined in panels D and E. DP values shown
for comparison are the same as in C.BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/12
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10-fold decrease in DP cell numbers [29]. Using BrdU
analysis, we compared the proliferation of Hoxa3+/-Pax1-/
- fetal thymocytes during the TN to DP transition com-
pared to littermate controls. Thymocyte proliferation lev-
els for all genotypes (Hoxa3+/-,Pax1+/-,  Pax1-/-, and
Hoxa3+/-Pax1-/-) were similar to wild type in all of the ca-
nonical TN1-TN4 stages (Fig. 2A,2B,2C; Table 1), consist-
ent with the normal percentages and cell numbers for
these subpopulations previously reported [29]. Recent pa-
pers by Penit, et al. have provided data from cell cycle
analysis suggesting that a discrete CD44-25lo population
with a specific proliferation profile can be identified, such
that the transition from TN3 to DP can be further subdi-
vided into CD25hi, CD25lo, and CD25- subsets [12,13].
Analysis of proliferation using these more narrowly de-
fined subsets still showed values similar to wild type in
the CD44-25lo subset (Fig. 2D,2E,2F; Table 2). In contrast,
the proliferation level of DP cells increased nearly 2-fold
in compound mutants compared to wild type (Fig. 2C, 2F;
Table 1). In spite of this increase in the percentage of pro-
liferating cells, the actual number of BrdU+ DP cells was
reduced 4-fold compared to wild type in the compound
mutants (15.03 ± 8.73 × 104 vs. 61.94 ± 32.12 × 104 in
wild type; p < 0.01). The numbers of proliferating cells at
the pre-DP stage were unchanged (not shown). Com-
bined with our previous results, this result shows that
both increased apoptosis and reduced proliferation con-
tribute to the decrease in DP cells in the Hoxa3,Pax1 com-
pound mutants. Unfortunately, Hoxa3+/-Pax1-/- mice die
at birth, preventing analysis of thymocyte proliferation in
adult compound mutants.
Cytokine production is decreased in the Hoxa3+/-Pax1-/- 
fetal thymus
Cytokines produced by TECs are good candidates for me-
diating at least some of these changes in thymocyte prolif-
eration and apoptosis in the Hoxa3,Pax1 compound
mutants. Using semi-quantitative RT-PCR, we analyzed
the expression of two cytokines that are produced by
TECs, IL-7 and SCF, in pooled, genotype-matched E14.5
thymi (Fig. 3). Hoxa3+/-Pax1-/- compound mutants had
decreased transcription of both cytokines relative to all
other genotypes, including Pax1-/- single mutants. Howev-
er,  Hoxa3+/-Pax1-/- compound mutants were not com-
pletely missing either cytokine analyzed, and the
magnitude of the decrease was variable between pools.
To test whether the changes in cytokine levels were re-
sponsible for the observed thymocyte development phe-
notypes, we attempted to rescue these phenotypes by
supplementation in fetal thymic organ culture (FTOC).
E15.5 embryonic thymic lobes from individual embryos
were cultured separately in FTOC, with or without added
IL-7 or SCF. Cultures from control genotypes (wild type,
Pax1+/-, Hoxa3+/-, Pax1-/-) behaved as expected [41–46],
with addition of IL-7 causing an increase in the percentage
of DN cells and a corresponding decrease in DP cells,
while adding SCF had no significant effect on thymocyte
development (data not shown). However, to our surprise
the two separated lobes from Hoxa3+/-Pax1-/- compound
mutants did not always develop in predictable ways. In
fact, separated lobes cultured under identical conditions
in the absence of any added cytokines had widely differing
results. Changes in thymocyte cell number and differenti-
ation after culture were highly variable; for example, cell
numbers could differ stochastically after culture by as
much as 10-fold between two lobes from the same com-
pound mutant embryo. This result was never obtained
with separately cultured thymic lobes from any other gen-
otype, which always developed identically when cultured
without cytokines. This property of the compound mu-
tant thymic lobes probably reflects phenotypic variability
previously seen in our histological and gross morpholog-
ical analysis of these mutants [29,34].
Discussion
In this study, we have examined thymocyte proliferation
in the fetal and adult wild type thymus. Our results
showed clear stage-specific differences in wild type thy-
mocyte proliferation depending on the developmental
age of the microenvironment (i.e. fetal vs. adult). We also
analyzed two mutant strains that have either cell-autono-
mous (Hoxa3+/-Pax1-/-) or non-cell-autonomous (Rag1-/-)
TEC defects, with blocks at different stages of thymocyte
differentiation. Abnormal TEC development in both of
these mutant strains resulted in both increases and de-
creases in thymocyte proliferation in a stage-specific man-
ner, rather than simply an overall reduced ability to
promote proliferation.
There is considerable evidence that thymopoiesis differs
in the fetal thymus during the initial creation of the micro-
environment, as opposed to adult thymus function (re-
viewed in [47]). Differences have been reported in
responses to some cytokines, in signaling at the TN-DP
transition in fetal compared to adult thymus, and in pro-
liferation of CD4+ SP thymocytes [36,48–50]. The prolif-
eration profiles of both wild type and Rag-/- fetal
thymocytes support the hypothesis that fetal thymocyte
maturation is fundamentally different from thymocyte
development in the adult thymus. The TN1 and DP stages
both show increased proliferation in wild-type fetal thy-
mocytes compared to adults. This difference at the TN1
stage is not due to the presence of more B or NK cells in
the adult thymus. Although it is formally possible that
some other cell type may still be included in our TN1 pop-
ulation, this analysis strongly suggests that TN1 cells have
different proliferation profiles in fetal and adult thymus.BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/12
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It has been well documented that thymocytes in adult
Rag1 or Rag2 mutants have dramatically reduced prolifer-
ation compared to wild type, particularly at the TN3 stage
[37–40], and Penit et al. reported 2–10 fold reductions at
every stage of thymocyte development in Rag-/- adults
[13]. Recent work by Petrie, et al. has shown that this
reduced proliferation is not intrinsic to Rag mutant thy-
mocytes, but rather is secondary to thymic micro-
environment defects in Rag mutants [37]. Our results
show that at fetal stages, Rag mutant thymocytes have a
proliferation profile that is much more similar to wild
type thymocytes at the same stage, with less than a 2-fold
difference in the percentage of proliferating cells at any
stage. For example, TN3 stage thymocytes in the Rag-/-
adult thymus have proliferation levels 3-fold below wild
type thymus [13,37], while in the Rag-/- fetal thymus TN3
cells are only 25–30% lower than in wild type fetal thy-
mus. Proliferation is not changed at all stages, and is actu-
ally increased relative to wild type at the TN2 stage. This
increase at the TN2 stage may be due to the failure of TN2
cells to initiate TCRβ gene rearrangement at this stage,
which is normally associated with decreased prolifera-
tion.Rag-/- mutants have a profound thymocyte develop-
ment block at the TN3 to TN4/preDP transition [51].
During normal wild type fetal thymus development, sig-
nificant DP cell development does not occur until E16.5
in most genetic backgrounds. As a result, at E17.5 the
thymic microenvironment in Rag mutants has not been
exposed to abnormal thymocyte development for very
long, and has not yet developed the full phenotype seen
in the steady state adult Rag mutant thymus [35].
In the Hoxa3,Pax1 compound mutants, cell-autonomous
TEC defects cause a partial block at the DN-DP transition,
so thymocytes do progress to DP and SP stages, albeit at
reduced frequencies [29]. TEC defects are seen as early as
E12.5 in these mutants, from the earliest stages of organo-
genesis [34]. Therefore, the TEC defects in these mice
would be expected to have different effects on thymocyte
proliferation than in Rag mutants. In this study, we found
stage-specific changes in thymocyte proliferation at the
DP stage. Our previous analysis reported decreased DP
cell number and increased apoptosis in both the pre-DP
and DP stages in these mutants [29]. DP cell numbers in
both this and our previous study were decreased 10-fold
in the Hoxa3+/-Pax1-/- compound mutants. At first glance,
the increase in the percentage of proliferating cells at the
DP stage appears contradictory to this phenotype. Howev-
er, this increase actually corresponds to decreased num-
bers of proliferating DP cells compared to wild type. In
contrast, pre-DP cells did not have a change in the number
or percentage of proliferating cells, suggesting that the sig-
nals promoting proliferation of these cells is still present,
and that proliferation of DP and pre-DP cells may be reg-
ulated independently. Pre-DP cells do have a three-fold
increase in apoptosis [29], suggesting that separate signals
regulate proliferation and survival of these cells. Com-
bined with our previous data, this result suggests that the
decrease in DP cell numbers seen in the Hoxa3-Pax1 com-
pound mutants is both due to an increase in the number
of pre-DP and DP cells undergoing apoptosis as well as a
decrease in the number of proliferating DP.
Insufficiencies of multiple cytokines might be involved in
the changes in proliferation and cell death at the CD44-
25- and DP stages in Hoxa3-Pax1 compound mutants. SCF
and IL-7 are first expressed as early as E12.5 in the devel-
oping thymus, well before significant thymocyte matura-
tion takes place [52,53]. Although the number of TECs is
reduced by about 2-fold in Hoxa3+/-Pax1-/- compound
mutants, the number of thymocytes is reduced by a slight-
ly greater amount, around 3-fold [29]. Therefore, the re-
ductions seen in cytokine message levels in the Hoxa3+/-
Pax1-/-compound mutants are not secondary to decreased
TEC numbers. In fact, these mutants should have a rela-
tive increase in the proportion of TECs, making the reduc-
tions seen in cytokine levels in the mutant thymi even
more striking. The reduced expression of these cytokines
in Hoxa3+/-Pax1-/- compound mutants could be an indi-
rect effect of defective TEC differentiation, or could be di-
rect downstream targets since both Hoxa3 and Pax1 are
expressed in fetal thymus [54,55]. Comparison of the
Hoxa3+/-Pax1-/- phenotype with those of cytokine mutants
do not reveal many similarities [30,46,56–61], probably
because of the simultaneous reductions in multiple cy-
tokines in the Hoxa3+/-Pax1-/- mutants. For example, SCF
Table 2: Percentages (Mean ± SD) of BrdU+ cells in selected subsets of wild-type and compound mutant fetal thymocytes
Genotype Total Cell
#(X105)
No. CD44- CD25hi CD44- CD25lo CD44- CD25- CD4+ CD8+ CD3+
Wild type 42.72 ± 3.88 23 16.91 ± 5.77 37.65 ± 12.77 42.45 ± 15.73 19.05 ± 8.12
Hoxa3+/-Pax1-/- 7.96 ± 1.12 6 16.66 ± 2.10 36.99 ± 9.067 44.49 ± 14.90 35.37 ± 6.41**
**P < 0.01, significant difference with wild type.BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/12
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and IL-7 have been shown to have synergistic functions
[62,63]. Therefore, changes in multiple cytokines in
Hoxa3+/-Pax1-/- mutants would be expected to have com-
plex effects on thymocyte development that could be dif-
ficult to predict.
Interpretation of the observed phenotype is further com-
plicated by the fact that none of the cytokines tested are
completely absent. A striking example is the complete ab-
sence of γδTCR+ thymocyte development in IL-7 mutants,
in contrast to normal γδTCR+ cell development in Hoxa3+/
-Pax1-/- mutants [29], which have dramatically reduced IL-
7 levels. This result suggests that although γδTCR+ cell de-
velopment requires IL-7, low levels are sufficient for this
function. Therefore, analysis of mutants with low levels of
cytokines may provide a system for uncovering both dos-
age-dependent requirements and later functions for these
factors in promoting thymocyte development. It is also
possible that some of the differences seen between
Hoxa3+/-Pax1-/- and cytokine mutant phenotypes reflect
different effects of cytokines at fetal and adult stages. Stud-
ies of IL-7R mutants showed relatively normal thymocyte
maturation at fetal stages, albeit with reduced thymocyte
numbers, in contrast to a severe block in thymocyte differ-
entiation in adult thymus [49]. Analysis of cytokine mu-
tants during fetal stages could therefore reveal a more
complete picture of the role of these cytokines during fetal
thymus development.
Conclusions
Our results show that fetal and adult wild type thymocytes
have stage-specific differences in proliferation, with both
TN1 and DP cells exhibiting higher levels of proliferation
in fetal thymus. This fetal wild-type profile was very simi-
lar to that seen for fetal Rag mutant thymocytes, in con-
trast to adult Rag-/- thymus. Therefore, the changes in
proliferation seen in the fetal Rag mutant thymocytes re-
flect the earliest microenvironment changes occurring as a
result of defective TEC-thymocyte interactions in the Rag-
/- thymus.
The current study further supports a role for TECs in regu-
lating both thymocyte proliferation and survival during
the DN-DP transition, and suggests that proliferation and
apoptosis of TN4 and DP cells are regulated independent-
ly. Our results provide direct genetic evidence for these
functions of TECs, by showing that these processes are de-
fective in mutants with a primary TEC differentiation de-
fect (the Hoxa3,Pax1 compound mutants). Taken
together, our results further define the role TECs play at
this complex stage of thymocyte development.
Methods
Mice and genotyping
Hoxa3+/-Pax1+/- mice were mated to Pax1+/- or Pax1-/-
mice and genotyped for both Hoxa3 and Pax1 by PCR as
described previously [29]. Comparisons were made be-
tween littermates from the same colony. Rag1-/- mice
(Jackson Labs) were maintained as a homozygous mutant
colony. All mice were maintained as congenic on a
C57BL/6 genetic background. Noon of the day of vaginal
plug was considered E0.5. All animal use procedures were
approved by the Medical College of Georgia Committee
on Animal Use for Research and Education (CAURE).
Flow cytometry
Fetal thymocyte in vivo BrdU incorporation was done by
intraperitoneal injection of BrdU (5-Bromo-2'-Deoxyuri-
dine; Sigma) on the morning of E17.5, two doses per
mouse and 1 mg per dose with a 0.5 hour pause, as previ-
ously described [13]. Two hours after the first injection, fe-
tal thymi were isolated by dissection and single-cell
suspensions prepared by passing the thymocytes through
cell strainers. Adult thymocyte in vivo BrdU incorporation
was done by the same injection protocol using 6–8 week
old C57BL/6 adult mice.
Figure 3
Expression of cytokines in fetal thymi of Hoxa3+/-
Pax1-/- mice and controls measured by semi-quanti-
tative RT-PCR Each lane contains pooled cDNA from 5–
10 E14.5 embryonic thymi of the same genotype. Represent-
ative results from one of three experiments for each
cytokine are shown. β-actin was used as a control. Panel A,
expression of IL-7; Panel B, expression of SCF.BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/12
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Four-color flow cytometry was performed using the fol-
lowing monoclonal antibodies (Pharmingen): biotin
anti-mouse CD25 (clone: 7D4) visualized with Per-CP
conjugated streptavidin; APC anti-mouse CD44 (clone:
IM7); and three phycoerythrin (PE) conjugated antibod-
ies: anti-mouse CD4 (clone: RM4-5), anti-mouse CD8a
(clone: 53–6.7), and anti-mouse CD3∈ (clone: 145-
2C11). In some experiments, PE conjugated antibodies
against B220 (clone: RA3-6B2) and NK1.1 (clone: PK136)
were also included. After cell surface staining, the cells
were fixed with 2% paraformaldehyde (PFA)/PBS at 4°C
overnight. The cells were then washed, permeabilized
with 0.1% Triton X-100/ 0.1% Na-Citrate (pH7.2) on ice
for 2 min, and then treated with 50 units of DNaseI at
37°C for 10 min. Cells were then stained with FITC anti-
BrdU antibody (Pharmingen). Data were collected by se-
lectively gating either CD3-4-8- or CD3+4+8+ populations
(Becton Dickinson dual laser FACSCalibur), and analyses
were performed with Cellquest software. Significant dif-
ferences were determined by the unpaired Student's t-test
or ANOVA analysis.
Semi-quantitative RT-PCR
E14.5 fetal thymic lobes were collected and stored in the
TRIzol (GIBCO BRL) at -70°C until RNA isolation. Pools
of 5-to10 thymi from embryos of the same genotype were
homogenized using Micro Pellet Pestles (Nalge Nunc In-
ternational) in 1.5 ml-eppendorf tubes. RNA was isolated
and the genomic DNA was depleted by using DNaseI
(Amplification Grade, GIBCO BRL) following the manu-
facturer's protocols. Reverse transcription of 1 µg of total
RNA to cDNA was done using SuperScript II following the
manufacturer's protocol (GIBCO BRL). Equal amounts of
cDNA from different genotypes were added to a final 20
µl PCR reaction mixture using the QIAGEN Taq PCR kits.
PCR conditions were: 94°C 30 sec, 50°C 1 min, 72°C 1
min for IL-7, SCF and their internal control β-actin; or
94°C 30 sec, 60°C 1 min, 72°C 1 min for TGFβ1 and its
internal control β-actin. PCR products were visualized by
5% acrylamide gel electrophoresis and ethidium bromide
staining. Band densities were measured and analyzed us-
ing the Molecular Analyst software package (Bio-Rad Lab-
oratories, Version 1.4.1). Primer sequences were: IL-7
[65]: IL-7 (5') 5'ACT ACA CCC ACC TCC CGC A3'; IL-7
(3') 5'TCT CAG TAG TCT CTT TAG G3'; SCF [65]: SCF (5')
5'TCT TCA ACT GCT CCT ATT T3'; SCF (3') 5'ACT GCT
ACT GCT GTC ATT C3'; TGFβ1 [66]: TGFβ1(5') 5'GCG
GAC TAC TAT GCT AAA GAG G3'; TGFβ1(3') 5'GTT GTG
TTG GTT GTA GAG GGC A3'; β-actin [67]: β-actin (5')
5'GGG TCA GAA GGA CTC CTA TG3'; β-actin (3') 5'GTA
ACA ATG CCA TGT TCA AT3'.
Fetal thymic organ culture (FTOC)
Thymic lobes were dissected from E15.5 embryos. The
two lobes from each embryo cultured separately in high
oxygen submersion culture as previously described [41].
Fetal thymic organ cultures were supplemented with 100
u/ml of IL-7 or 20 ng/ml of SCF (Pepro Tech Inc.) as pre-
viously described [41]. For each embryo, one lobe was
treated while the other was cultured in parallel without
supplemental cytokine as an internal control. In control
experiments, lobes were cultured separately under identi-
cal conditions without cytokine. After five days in culture,
the cells were stained by PE-anti-mouse CD4 and FITC-
anti-mouse CD8 and analyzed by flow cytometry as
above.
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